Watch BGLC. Know when insiders buy.
One email the day a filing lands. Free.
BGLC
BioNexus Gene Lab Corp
1.40
−0.05 −3.45%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
20
FLAG · shorts 20
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.1MP/E —DIV YIELD —FCF YIELD -20.78%REV TTM $3.1M −67.3%NET INCOME −$2.6MNET CASH —52W 1.32 – 6.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $76K | −96.6% | 17.0% | −$282K | −$286K | — | -0.12 | −$422K | $250 | −$423K | Aug 14 |
| Q1 2026 · Mar 31 | $23K | −98.9% | -3.5% | −$540K | −$544K | — | -0.23 | −$148K | $325 | −$148K | Aug 14 |
| Q4 2025 · Dec 31derived | $484K | −80.8% | -0.8% | −$1M | −$1M | — | — | $961K | $977 | $960K | Apr 14 |
| Q3 2025 · Sep 30 | $2.5M | −3.3% | 14.8% | −$703K | −$709K | — | -0.40 | −$1.2M | $5K | −$1.2M | Nov 14 |
| Q2 2025 · Jun 30 | $2.3M | +14.5% | 16.3% | −$611K | −$616K | −409.5% | -0.34 | −$738K | $21K | −$759K | Aug 14 |
| Q1 2025 · Mar 31 | $2.1M | −10.3% | 16.1% | −$618K | −$623K | — | -0.35 | −$824K | $9K | −$833K | Aug 14 |
| Q4 2024 · Dec 31derived | $2.5M | +11.0% | 12.3% | −$416K | −$348K | −212.9% | 0.61 | $219K | $4K | $215K | Apr 14 |
| Q3 2024 · Sep 30 | $2.6M | +3.0% | 12.4% | −$1.3M | −$1.3M | — | -0.75 | −$1.6M | $199K | −$1.8M | Nov 14 |
| Q2 2024 · Jun 30 | $2M | — | 14.6% | $259K | $199K | — | 0.11 | −$672K | $2K | −$674K | Aug 18 |
| Q1 2024 · Mar 31 | $2.4M | — | 15.3% | −$79K | −$104K | — | -0.01 | −$37K | $22K | −$59K | May 15 |
| Q4 2023 · Dec 31derived | $2.3M | — | 11.7% | $258K | $308K | — | — | −$783K | $937 | −$783K | Apr 15 |
| Q3 2023 · Sep 30 | $2.6M | — | 13.9% | −$2.5M | −$2.6M | — | — | −$899K | $134K | −$1M | Nov 15 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.4M | 14.6% | −$3M | −$3M | -40.2% | — | −$1.8M | $37K | −$1.9M | — | — |
| FY2024 · to Dec 31 | $9.5M | 13.6% | −$1.6M | −$1.6M | -16.8% | -0.09 | −$2.1M | $227K | −$2.3M | — | — |
| FY2023 · to Dec 31 | $9.8M | 13.6% | −$2.6M | −$2.6M | -26.9% | -0.17 | −$1.8M | $149K | −$2M | — | — |
| FY2022 · to Dec 31 | $10.9M | 11.5% | −$291K | −$356K | -3.3% | — | $552K | $0 | $552K | — | — |
| FY2021 · to Dec 31 | $13.4M | 17.0% | $1.1M | $752K | 5.6% | — | $9K | $3K | $6K | — | — |
| FY2020 · to Dec 31 | $11.4M | 15.1% | $1.3M | $1.1M | 9.6% | 0.01 | $553K | $422K | $131K | — | — |
Every number comes from BioNexus Gene Lab Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.